We are live on ! Find out more
MBII

Marrone Bio Innovations, Inc.

Delisted

MBII was delisted on the 12th of July, 2022.

0 hedge funds and large institutions have $0 invested in Marrone Bio Innovations, Inc. in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 620 (-62)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

100% less capital invested

Capital invested by funds: $45M → $0 (-$45M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 62

Holders
Holders Change
-62
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
62
Calls
Puts
Net Calls
Net Calls Change

MBII Hedge Fund Activity: Q3 2022 in Review

0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Marrone Bio Innovations, Inc. (MBII) for Q3 2022, worth a combined $0 — down 100% from $45M a quarter earlier.

Sellers outnumbered buyers: 62 funds closed out of MBII and 0 opened new positions — a net loss of 62 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Ardsley Advisory Partners, exiting entirely with an estimated $21.3M sold.

  • 0 institutional investors held Marrone Bio Innovations, Inc. (MBII) as of Q3 2022, down from 62 in Q2 2022.
  • Funds reported $0 of Marrone Bio Innovations, Inc. stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Marrone Bio Innovations, Inc. positions in Q3 2022 and 62 closed out, a net change of -62 holders.
  • The largest Marrone Bio Innovations, Inc. seller in Q3 2022 was Ardsley Advisory Partners, an estimated $21.3M sold.

Based on aggregated 13F filings for Q3 2022.